cefetamet has been researched along with Sepsis* in 1 studies
1 other study(ies) available for cefetamet and Sepsis
| Article | Year |
|---|---|
In vitro antibacterial properties of cefetamet and in vivo activity of its orally absorbable ester derivative, cefetamet pivoxil.
The in vitro activity of cefetamet, the microbiologically active metabolite of the orally administered prodrug cefetamet pivoxil, was compared with that of cephalexin, cefaclor, cefuroxime and amoxicillin. Cefetamet was highly active against Enterobacteriaceae, Neisseria spp., Vibrio spp., Haemophilus influenzae and streptococci other than enterococci. Cefetamet inhibited cefaclor-resistant species such as Proteus vulgaris, Providencia stuartii, Providencia rettgeri and Serratia marcescens. Staphylococci, Pseudomonas aeruginosa and cephalosporinase-overproducing strains of Enterobacter cloacae were resistant to cefetamet. The superior activity of cefetamet compared with older oral beta-lactam antibiotics against a large number of gram-negative pathogens correlated with enhanced stability towards beta-lactamases. In accordance with the in vitro findings, cefetamet pivoxil showed good activity in experimental infections in the mouse and rat, suggesting satisfactory bioavailability in these animals after oral administration. Topics: Animals; Bacteria; Bacterial Proteins; beta-Lactamases; Carrier Proteins; Ceftizoxime; Drug Resistance, Microbial; Enterobacteriaceae; Haemophilus influenzae; Hexosyltransferases; Humans; Mice; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Neisseria; Penicillin-Binding Proteins; Peptidyl Transferases; Rats; Sepsis; Streptococcus; Vibrio | 1989 |